[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-468705-105":59,"doc-detail-468705-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","causal-relationships-between-blood-metabolites-cognitive-outcomes-brain-imaging-and-csf-biomarkers-in-alzheimers-disease-poster-presentation","Causal Relationships Between Blood Metabolites, Cognitive Outcomes, Brain Imaging, and CSF Biomarkers in Alzheimer’s Disease - Poster Presentation","","Alzheimer’s Disease is characterized by cognitive decline and metabolic dysregulation, yet it is unclear whether blood metabolites cause disease or only mirror progression. Using Aitia’s AD Digital-Twin, a virtual cohort built from ~59k clinical and multi-omic variables, a causal Bayesian network linked 122 serum metabolites and 20 bile acids to CSF biomarkers, MRI subcortical measures, and cognition. The study found 44 cognition-related causal metabolites, including amino acids that drive baseline cognition and brain structural changes, and identified Tau-influenced metabolic alterations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/causal-relationships-between-blood-metabolites-cognitive-outcomes-brain-imaging-and-csf-biomarkers-in-alzheimers-disease-poster-presentation/468705/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/causal-relationships-between-blood-metabolites-cognitive-outcomes-brain-imaging-and-csf-biomarkers-in-alzheimers-disease-poster-presentation/468705.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this poster study?","Question",{"text":112,"@type":113},"To determine whether blood metabolites causally drive Alzheimer’s Disease progression or mainly reflect it, by linking metabolites to CSF biomarkers, cognition, and brain structure using a causal modeling approach.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the analysis performed in the study?",{"text":117,"@type":113},"Aitia’s AD Digital-Twin was used, building a causal Bayesian network over metabolites, CSF biomarkers, MRI-derived subcortical measures, and cognitive outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biological signals were highlighted as key drivers?",{"text":121,"@type":113},"Tau pathology, hippocampal atrophy, and glucose hypometabolism were emphasized as central in driving metabolic alterations, with many cognition-related metabolites influenced by Tau and related measures.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},468705,1792834315,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":24,"preview_page_count":14,"preview_urls":144},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","DOI: 10. 1002/alz70856_107374  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nCausal Relationships Between Blood Metabolites, Cognitive Outcomes, Brain Imaging, and CSF Biomarkers in Alzheimer’s Disease: Insights from Digital-Twins  \nApoorva Bharthur Sanjay  Deepanshi Shokeen  Jeanne Latourelle  So-Youn Shin  \nAitia, Somerville, MA, USA  \nCorrespondence  \nJeanne Latourelle, Aitia, Somerville, MA, USA. [Email:](Email: jlatoure@aitiabio.com)[ jlatoure@aitiabio.com](Email: jlatoure@aitiabio.com)  \nAbstract  \nBackground: Alzheimer’s Disease (AD) is marked by cognitive decline and metabolic dysregulation, with blood metabolites playing a crucial role in disease progression. However, it remains unclear whether these metabolites actively drive the disease or merely reflect its progression. Identifying causal metabolites and understanding their relationships with biomarkers, cognition, and brain structure could provide new insights into AD pathogenesis and potential therapeutic strategies.  \nMethod: Aitia’s AD Digital-Twin is a virtual model of AD patients and controls, built using ∼59k clinical and multi-omic variables from ADNI, including 122 serum metabolites profiled by Biocrates AbsoluteIDQ p180 and 20 bile acids from Bile Acids Kit. Using the causal Bayesian network structure within AD Digital-Twins, we investigated cause-and-effect relationships between metabolites, cerebrospinal fluid (CSF) biomarkers, MRI-derived subcortical measures, and cognitive outcomes.  \nResult: We identified 44 metabolites (31% of 142) causally related to cognitive outcomes, with nine metabolites driving baseline cognitive function rather than the rate of cognitive decline. Two amino acids, Isoleucine and Lysine, influence both the MMSE score and the thickness of the entorhinal cortex and middle temporal region volume. These amino acids are novel causal drivers of brain structural changes in AD. Additionally, medium-chain triglycerides (MCTs) and a sphingomyelin were found to drive changes in middle temporal volume and baseline values, respectively. MCTs are known to enhance brain energy metabolism, and sphingomyelins maintain neuronal membrane integrity, suggesting their central role in neurodegeneration.  \nNotably, 15 of the 44 cognition-related metabolites were driven by CSF Tau & pTau, hippocampal volume, and FDG hypometabolism, highlighting that many metabolic changes observed in association studies may be reactions to biomarker changes. The causal relationship with Tau suggests that AD-related metabolites are primarily influenced by tau pathology rather than amyloid-beta.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e107374.  \n[https://doi.org/10.1002/alz70856_107374](https://doi.org/10.1002/alz70856_107374)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nConclusion: These findings highlight the critical role of Tau pathology, hippocampal atrophy, and glucose hypometabolism in driving metabolic alterations in AD. Some metabolites are causal drivers of cognitive decline and neurodegeneration, while others reflect disease progression, offering potential biomarkers for early diagnosis and treatment. Future work integrating transcriptomic and genotypic data with metabolomics could identify key pathways, advancing our understanding of the genetic and molecular drivers of AD.","cbCaimwLtu1VrXBN","https://ap.wps.com/l/cbCaimwLtu1VrXBN","pdf",87908,"English","# Background\n# Method\n# Result\n# Conclusion","[{\"question\":\"What is the main goal of this poster study?\",\"answer\":\"To determine whether blood metabolites causally drive Alzheimer’s Disease progression or mainly reflect it, by linking metabolites to CSF biomarkers, cognition, and brain structure using a causal modeling approach.\"},{\"question\":\"How was the analysis performed in the study?\",\"answer\":\"Aitia’s AD Digital-Twin was used, building a causal Bayesian network over metabolites, CSF biomarkers, MRI-derived subcortical measures, and cognitive outcomes.\"},{\"question\":\"Which biological signals were highlighted as key drivers?\",\"answer\":\"Tau pathology, hippocampal atrophy, and glucose hypometabolism were emphasized as central in driving metabolic alterations, with many cognition-related metabolites influenced by Tau and related measures.\"}]","Causal Relationships Between Blood Metabolites, Cognitive Outcomes, Brain Imaging, and CSF Biomarkers in Alzheimer’s Disease - Poster Presentation | PDF",1790774549,[145,149],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/623242af4c679bafc7bd2157eab907a5.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b153af4d552950b5332d385359d50820.webp",982,1290]